Method for the secondary prevention of ischemic events

Abstract

The invention relates to a new method for the secondary prevention of ischemic events comprising administering to a man in need thereof a therapeutically effective amount of a compound selected from clopidogrel and its pharmaceutically acceptable acid addition salts in association with a pharmaceutically acceptable carrier.

We claim: 
     
       1. A method for preventing the occurrence of a secondary ischemic event comprising administering to a patient who has suffered a primary ischemic event a therapeutically effective amount of a compound selected from clopidogrel and a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier. 
     
     
       2. The method according to claim 1, wherein the primary and/or secondary ischemic event is a myocardial infarction. 
     
     
       3. The method according to claim 1, wherein the primary and/or secondary ischemic event is unstable or stable angina. 
     
     
       4. The method according to claim 1, wherein the primary and/or secondary ischemic event is acute reocclusion after percutaneous transluminal coronary angioplasty. 
     
     
       5. The method according to claim 1, wherein the primary and/or secondary ischemic event is restenosis. 
     
     
       6. The method according to claim 1, wherein the primary and/or secondary ischemic event is thrombotic stroke. 
     
     
       7. The method according to claim 1, wherein the primary and/or secondary ischemic event is a transient ischemic attack. 
     
     
       8. The method according to claim 1, wherein the primary and/or secondary ischemic event is reversible ischemic neurological deficit. 
     
     
       9. The method according to claim 1, wherein the primary or secondary ischemic event is intermittent claudication. 
     
     
       10. A method according to claim 1, in which said acid addition salt is the hydrogen-sulfate. 
     
     
       11. A method according to claim 1, wherein the route of administration of the compound is either the oral route or the intravenous route. 
     
     
       12. A method according to claim 1, wherein the compound is orally administered in a daily amount varying from 25 to 600 mg. 
     
     
       13. A method according to claim 1, wherein the compound is orally administered in a daily amount of 75 mg. 
     
     
       14. A method according to claim 1, wherein the administration of the compound is concomitant to the administration of aprotinin. 
     
     
       15. The method according to claim 1, wherein said compound is selected from clopidogrel and clopidogrel hydrogen-sulfate said compound being administered in combination with a thrombolytic agent. 
     
     
       16. The method according to claim 15, wherein the thrombolytic agent is streptokinase. 
     
     
       17. The method of claim 15, wherein the compound is clopidogrel hydrogen-sulfate. 
     
     
       18. The method of claim 14, wherein the compound is clopidogrel hydrogen-sulfate. 
     
     
       19. The method of claim 1, wherein the compound is clopidogrel hydrogen-sulfate. 
     
     
       20. A method of preventing ischemia-induced secondary ischemia comprising administering to a patient who has suffered an ischemic event a therapeutically effective amount of a compound selected from clopidogrel and a pharmaceutically acceptable acid addition salt thereof, together with a pharmaceutically acceptable carrier.